RGLS vs. LLY

In the year-to-date period, RGLS achieves a -17.09% return, which is significantly lower than LLY's 13.37% return. Over the past 10 years, RGLS has underperformed LLY with an annualized return of -52.41%, while LLY has yielded a comparatively higher 31.03% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Regulus Therapeutics Inc. (RGLS) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RGLS Sharpe Ratio is -0.15, which is lower than the LLY Sharpe Ratio of 0.53. The chart below compares the historical Sharpe Ratios of RGLS and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

RGLS has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.62%.

The maximum RGLS drawdown since its inception was -99.97%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for RGLS and LLY. For additional features, visit the drawdowns tool.

Regulus Therapeutics Inc. (RGLS) has a higher volatility of 33.47% compared to Eli Lilly and Company (LLY) at 7.16%. This indicates that RGLS's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Regulus Therapeutics Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.